Antiangiogenic agents in cancer therapy
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
2008
|
| Ausgabe: | 2. ed. |
| Schriftenreihe: | Cancer drug discovery and development
[3] |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Klappentext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV023334704 | ||
| 003 | DE-604 | ||
| 005 | 20080709 | ||
| 007 | t| | ||
| 008 | 080609s2008 xx ad|| |||| 00||| eng d | ||
| 020 | |a 9781588298706 |9 978-1-58829-870-6 | ||
| 035 | |a (OCoLC)222132022 | ||
| 035 | |a (DE-599)BVBBV023334704 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a RC271.N46 | |
| 082 | 0 | |a 616.99/4061 |2 22 | |
| 084 | |a XI 7000 |0 (DE-625)153024:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Antiangiogenic agents in cancer therapy |c ed. by Beverly A. Teicher ... |
| 250 | |a 2. ed. | ||
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2008 | |
| 300 | |a XVIII, 559 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Cancer drug discovery and development |v [3] | |
| 650 | 4 | |a Antineoplastic Agents |x therapeutic use | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 4 | |a Neovascularization inhibitors | |
| 650 | 4 | |a Neovascularization, Pathologic |x drug therapy | |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Vaskularisation |0 (DE-588)4187429-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Angiogenese |0 (DE-588)4142449-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Inhibition |0 (DE-588)4273127-6 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Angiogenese |0 (DE-588)4142449-9 |D s |
| 689 | 0 | 2 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Vaskularisation |0 (DE-588)4187429-8 |D s |
| 689 | 1 | 2 | |a Inhibition |0 (DE-588)4273127-6 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Teicher, Beverly A. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-1-59745-184-0 |
| 830 | 0 | |a Cancer drug discovery and development |v [3] |w (DE-604)BV011340435 |9 3 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016518587&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016518587&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |3 Klappentext |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-016518587 | |
Datensatz im Suchindex
| _version_ | 1819726166122037248 |
|---|---|
| adam_text | Contents
Preface
........................................................................................................................
v
Contributors
................................................................................................................ xi
List of Color Plates
.................................................................................................... xv
Part I. Basic Biology of Angiogenesis
1
Vascular Endothelial Growth Factor Family and Its Receptors
................... 3
Daniel]. Hicklin
2
The Cycle Between Angiogenesis,
Perfusion,
and Hypoxia in Tumors
.............................................................................. 27
Mark W. Dewhirst, Yiting
Cao,
and Gordana Vlahovic
3
The Role of
Integrins
in Tumor Angiogenesis
.............................................. 49
Арата
R.
Aiyer and Judith A. Varner
4
Tumor Endothelial Cell Abnormalities
.......................................................... 73
Andrew C. Dudley and Michael Klagsbrun
5
The Extracellular Matrix and VEGF Processing
........................................... 85
Sunyoung Lee and M.
Luisa Iruela-Arispe
6
Endothelial Precursor Cells
............................................................................ 99
Rebecca G. Bagley
7
Role of Pericytes in Angiogenesis
.................................................................117
Chunhua
Lu
and Anil K. Sood
8
Newer Vascular Targets
.................................................................................133
Beverly A. Teicher
9
Chemokines in Angiogenesis
.........................................................................155
Michael P.
Keane,
John A. Belperio, and Robert M. Strieter
10
Angiopoietin/TieZ Signaling Regulates Tumor Angiogenesis
......................171
Hanako Kobayashi, Laura M. DeBusk, and P. Charles Lin
11
Imaging Angiogenesis
....................................................................................189
Sanjeeva P.
Kalva, Saravanan Namasivayam,
and Dushyant Vasuedeo
Sahani
12
Tumor Blood Vessels: Structure, Function, and Classification
...................205
Yineng
Fu,
Janice
A. Nagy,
Ann M. Dvorak,
and Harold F. Dvorak
13
Lymphatic System in the Pathology of Cancer
.............................................225
Bronislaw Pytowski
Contents
Part IL Translational Research in
Tumor Angiogenesis
14
VEGF
in the Adult:
Implications
for Anti-VEGF Therapies
........................245
Arindel
S. R.
Maharaj and Patricia
A. D Amore
15
Normalization of Tumor Vasculature and
Microenvironment:
A Potential
Mechanism of Action of Antiangiogenic Therapies
...................................261
Rakesh K. Jain, Tracy T. Batchelor, Dan G.
Duda,
and Christopher G. Willett
16
Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice
and Man
......................................................................................................277
Robert S.
Kerbel,
U.
Emmenegger,
S.
Man,
R.
Muñoz,
С.
Folkins, and Y.
Shaked
17
Small-Molecule Vascular Disrupting Agents in Cancer Therapy
.................297
Dietmar
W.
Siemann
and Michael
R.
Horsman
18
Normalization of Tumor Vasculature and Improvement of Radiation
Response by Antiangiogenic Agents
.........................................................311
Erin
Mendoza,
Randy
Burd,
Phyllis Wachsberger,
and Adam P. Dicker
19
Challenges in Translating Antiangiogenic Therapy
from the Bench to Bedside
.........................................................................323
Lee M. Ellis, Nikolaos A. Dallas, George van
Buren
Π,
Sherry
Lim,
Ling Xia, Fan Fan, and Michael J. Gray
20
Regulation of Angiogenesis in Cancer and Its Therapeutic Implications
....331
Liangfeng Han, Annaka M. Lorincz, and Saraswati Sukumar
Part III. Antiangiogenic Therapy in the Clinical Trial
Results and Future Directions
21
Angiogenesis and Angiogenesis Inhibition in Sarcomas
..............................353
Steven DuBois and George
Demetri
22
Antiangiogenesis Agents in Colorectal Cancer
.............................................371
Axel Grothey
23
Antiangiogenic Therapy for Primary CNS Tumors
......................................385
Katherine
E.
Warren and Howard A. Fine
24
Angiogenesis Inhibitors for the Treatment of Lung Cancer
.........................409
Monique
B. Nilsson, Emer O. Hanrahan,
and John V.
Heymach
25
Antiangiogenic Therapy of Renal Cell Carcinoma
.......................................427
Michael S. Gordon and Scot W. Ebbinghaus
26
Antiangiogenesis Therapies in Gynecologic Malignancies
...........................441
Robert A, Burger
27
Antiangiogenic Agents in Myeloid Malignancies
.........................................457
Magda
Melchert and Alan F. List
Contents
28 Angiogenesis in
Malignant and
Non-Malignant
Pediatrie
Tumors..............475
Domenico Ribatti
and Mirco Ponzoni
29
Prognostic and Predictive Significance of
Surrogate
Biomarkers
of
Angiogenesis..........................................................................................487
Raffaele
Longo,
Francesco Tonno, and Giampietro Gasparini
30 Endpoints
for the Determination of Efficacy of Antiangiogenic Agents
in Clinical Trials
.........................................................................................509
Joseph Paul
Eder
and Dan S. Zuckerman
31
The Role of Imaging in the Clinical Development
of Antiangiogenic Agents
...........................................................................525
Andrew R. Clamp and Gordon C. Jayson
Index
...........................................................................................................................537
CANCER
DRUG DISCOVERY AND DEVELOPMENT
Series Editor: Beverly A. Teicher
Antiangiogenic Agents In Cancer Therapy
Second Edition
Edited by
Beverly A. Teicher
Genzyme Corporation, Framingham, MA
Lee M. Ellis
Trie University of Texas M. D. Anderson Cancer Center, Houston,
TX
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to
emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.
Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the
armamentarium to fight cancer will be an ongoing challenge. Antiangiogenic Agents in Cancer Therapy, Second
Edition provides a current, updated perspective on the state of the art of angiogenesis and therapy with a
compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field
present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities
that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor
angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans.
Comprehensive and cutting-edge,
Anüangiogenic
Agents in Cancer Therapy, Second Edition is an ideal, valuable
guide to the most recent advances in the field, and a collection that will be useful for many years to come.
■
Current perspectives on state-of-the-art therapies
■
Contains chapters specific to angiogenesis and
antiangiogenic treatment of many malignant diseases
Contents
Part I. Basic Biology of Angiogenesis. Vascular Endothelial Growth Factor Family and its Receptors.The
Cycle Between Angiogenesis,
Perfusion,
and Hypoxia in Tumors.The Role of
Integrins
in Tumor Angiogenesis.
Tumor Endothelial Cell Abnormalities.The Extracellular Matrix andVEGF Processing. Endothelial Precursor
Cells. Role of Pericytes in Angiogenesis. Newer Vascular Targets. Chemokines in Angiogenesis. Angiopoietin/
Tie2 Signaling Regulates Tumor Angiogenesis. Imaging Angiogenesis. Tumor Blood Vessels: Structure and
Function. Lymphatic System in the Pathology of Cancer. Part Il.Translational Research in Tumor Angio¬
genesis. VEGF in the Adult: Implications for
Antî-VEG F
Therapies. Normalization of Tumor Vasculature and
Microenvironment.
Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man. Small-Molecule
Vascular Disrupting Agents in Cancer Therapy. Normalization of Tumor Vasculature and Improvement of
Radiation Response by Antiangiogenic Agents. Challenges in Translating Antiangiogenic Therapy from the Bench
to Bedside. Regulation of Angiogenesis in Cancer and Its Therapeutic Implications. Part III. Antiangiogenic
Therapy in the Clinical Trial Results and Future Directions. Angiogenesis and Angiogenesis Inhibition
in Sarcomas. Antiangiogenesis Agents in Colorectal Cancer. AntiangiogenicTherapy for Primary CNSTumors.
Angiogenesis Inhibitors for the Treatment of Lung Cancer. Antiangiogenic Therapy of Renal Cell Carcinoma.
Antiangiogenesis Therapies in Gynecologic Malignancies. Antiangiogenic Agents in Myeloid Malignancies.
Angiogenesis in Malignant and Non-Malignant
Pediatrie
Tumors. Prognostic and Predictive Significance of
Surrogate
Biomarkers
of Angiogenesis.
Endpoints
for the Determination of Efficacy of Antiangiogenic Agents
in Clinical Trials.The Role of Imaging in the Clinical Development of Antiangiogenic Agents. Index.
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV023334704 |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.N46 |
| callnumber-search | RC271.N46 |
| callnumber-sort | RC 3271 N46 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XI 7000 |
| ctrlnum | (OCoLC)222132022 (DE-599)BVBBV023334704 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 2. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02542nam a2200577 cb4500</leader><controlfield tag="001">BV023334704</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080709 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">080609s2008 xx ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781588298706</subfield><subfield code="9">978-1-58829-870-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)222132022</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023334704</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC271.N46</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 7000</subfield><subfield code="0">(DE-625)153024:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiangiogenic agents in cancer therapy</subfield><subfield code="c">ed. by Beverly A. Teicher ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVIII, 559 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Cancer drug discovery and development</subfield><subfield code="v">[3]</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neovascularization inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neovascularization, Pathologic</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Vaskularisation</subfield><subfield code="0">(DE-588)4187429-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Angiogenese</subfield><subfield code="0">(DE-588)4142449-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Inhibition</subfield><subfield code="0">(DE-588)4273127-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Angiogenese</subfield><subfield code="0">(DE-588)4142449-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Vaskularisation</subfield><subfield code="0">(DE-588)4187429-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Inhibition</subfield><subfield code="0">(DE-588)4273127-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teicher, Beverly A.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-1-59745-184-0</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Cancer drug discovery and development</subfield><subfield code="v">[3]</subfield><subfield code="w">(DE-604)BV011340435</subfield><subfield code="9">3</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016518587&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016518587&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Klappentext</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016518587</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV023334704 |
| illustrated | Illustrated |
| indexdate | 2024-12-23T21:01:53Z |
| institution | BVB |
| isbn | 9781588298706 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016518587 |
| oclc_num | 222132022 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XVIII, 559 S. Ill., graph. Darst. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Humana Press |
| record_format | marc |
| series | Cancer drug discovery and development |
| series2 | Cancer drug discovery and development |
| spellingShingle | Antiangiogenic agents in cancer therapy Cancer drug discovery and development Antineoplastic Agents therapeutic use Neoplasms drug therapy Neovascularization inhibitors Neovascularization, Pathologic drug therapy Pharmakotherapie (DE-588)4076066-2 gnd Krebs Medizin (DE-588)4073781-0 gnd Vaskularisation (DE-588)4187429-8 gnd Angiogenese (DE-588)4142449-9 gnd Inhibition (DE-588)4273127-6 gnd |
| subject_GND | (DE-588)4076066-2 (DE-588)4073781-0 (DE-588)4187429-8 (DE-588)4142449-9 (DE-588)4273127-6 (DE-588)4143413-4 |
| title | Antiangiogenic agents in cancer therapy |
| title_auth | Antiangiogenic agents in cancer therapy |
| title_exact_search | Antiangiogenic agents in cancer therapy |
| title_full | Antiangiogenic agents in cancer therapy ed. by Beverly A. Teicher ... |
| title_fullStr | Antiangiogenic agents in cancer therapy ed. by Beverly A. Teicher ... |
| title_full_unstemmed | Antiangiogenic agents in cancer therapy ed. by Beverly A. Teicher ... |
| title_short | Antiangiogenic agents in cancer therapy |
| title_sort | antiangiogenic agents in cancer therapy |
| topic | Antineoplastic Agents therapeutic use Neoplasms drug therapy Neovascularization inhibitors Neovascularization, Pathologic drug therapy Pharmakotherapie (DE-588)4076066-2 gnd Krebs Medizin (DE-588)4073781-0 gnd Vaskularisation (DE-588)4187429-8 gnd Angiogenese (DE-588)4142449-9 gnd Inhibition (DE-588)4273127-6 gnd |
| topic_facet | Antineoplastic Agents therapeutic use Neoplasms drug therapy Neovascularization inhibitors Neovascularization, Pathologic drug therapy Pharmakotherapie Krebs Medizin Vaskularisation Angiogenese Inhibition Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016518587&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016518587&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV011340435 |
| work_keys_str_mv | AT teicherbeverlya antiangiogenicagentsincancertherapy |